Duvelisib
Duvelisib is a pharmaceutical drug with 39 clinical trials. Currently 8 active trials ongoing. Historical success rate of 65.0%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
18
Early Stage
15
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
13 of 26 finished
50.0%
13 ended early
8
trials recruiting
39
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Clinical Trials (39)
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 39